A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

Inclusion Criteria:

• Participants need to be between 18 and 65 years old.

• Participants must have access to a participating clinical research site and bewilling to follow the study schedule.

• Participants should understand the study details and be willing to give informedconsent.

• Participants must agree not to join any other clinical trials until they finish thisstudy.

• Participants must be willing to receive HIV test results.

• Participants should be open to discussing HIV prevention.

• Clinic staff should assess participants as having a low risk of getting HIV, andparticipants must commit to avoiding high-risk behaviors during the study.

• Hemoglobin: Participant meets minimum levels depending on gender and hormone therapystatus.

• White Blood Cells (WBC): Should be within the normal range or approved by a siteclinician.

• Platelets: At least 100,000 cells/mm³.

• Alanine aminotransferase (ALT): Less than 5 times the upper normal limit.

• Creatinine: Less than 1.8 times the upper normal limit or less than 1.5 times yourbaseline level.

• Participants must test negative for HIV-1 and HIV-2.

• Participants urine protein must be negative or trace.

Reproductive Status:

• Participants of child-bearing potential need a negative pregnancy test within 72hours before starting the study.

• Participants must agree to use effective birth control from at least 21 days beforejoining the study until the end of the study.

• Participants must agree not to try to become pregnant through any method during thestudy.

Exclusion Criteria:

• Participants cannot have had a blood transfusion within the last 120 days.

• Participants cannot have received experimental treatments within the last 30 days.

• Participants cannot weigh less than 35 kg (about 77 lbs).

• Participants cannot plan to join another clinical trial during this study.

• Participants cannot be pregnant or breastfeeding.

• Participants cannot have received an HIV vaccine in a previous trial (unless it wasa placebo, subject to Protocol Safety Review Team's approval).

• Participants cannot have had any live vaccines within the last 14 days or non-livevaccines within the last 7 days.

• Participants cannot have had humanized or human monoclonal antibodies recently,except for certain HIV antibodies more than 12 months ago.

• Participants cannot have had allergy shots within the last 14 days.

• Participants cannot have taken immunosuppressive drugs within the last 30 days, withsome exceptions like nasal sprays or mild skin treatments.

• Participants cannot participate if they have had serious allergic reactions to thecomponents of the study product.

• Participants cannot have received immunoglobulin within the last 60 days.

• Participants cannot have an autoimmune disease that requires immunosuppressivetreatment, unless it's mild and stable.

• Participants cannot have an immune system deficiency.

• Participants cannot have any significant medical condition or abnormal lab resultsthat could impact their health during the study.

• Participants cannot have conditions that make repeated injections or blood drawsdifficult.

• Participants cannot have conditions requiring active medical treatment that couldpose a risk during the study.

• Participants cannot have conditions that could be confused with reactions to thestudy product.

• Participants cannot have medical, social, or occupational conditions that wouldinterfere with the study.

• Participants cannot have severe psychiatric conditions, like ongoing risk of suicideor recent history of suicide attempts.

• Participants cannot be undergoing treatment for tuberculosis.

• Participants cannot have severe asthma that requires frequent medication oremergency care.

• Participants cannot have diabetes mellitus (DM) (well-controlled Type 2 DM or anisolated history of gestational diabetes are not exclusionary).

• Participants blood pressure must be below 160/110 mmHg.

• Participants cannot have any diagnosed bleeding disorders.

• Participants cannot have active cancer but may be eligible if, in the investigator'sestimation, they have a reasonable assurance of sustained cure, or are unlikely toexperience recurrence of malignancy during the period of the study

• Participants cannot have had seizures or taken seizure medications in the past 3years.

• Participants cannot have a history of severe allergic reactions like anaphylaxis,unless it has been well-controlled for at least 5 years.

• Participants cannot have acute or unstable hepatitis B or C, but stable chroniccases may be considered.